Jump to content

CBS-0550

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dcirovic (talk | contribs) at 17:52, 28 May 2016 (clean up using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

CBS-0550
Identifiers
  • N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23F4N3O
Molar mass397.409 g/mol g·mol−1
3D model (JSmol)
  • C3CC3Cn1c(cc(C(C)(C)C)n1C)=N\C(=O)c2cccc(C(F)(F)F)c2F
  • InChI=1S/C20H23F4N3O/c1-19(2,3)15-10-16(27(26(15)4)11-12-8-9-12)25-18(28)13-6-5-7-14(17(13)21)20(22,23)24/h5-7,10,12H,8-9,11H2,1-4H3/b25-16+
  • Key:PABOWKPYVAFTRN-PCLIKHOPSA-N

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]

See also

References

  1. ^ Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322
  2. ^ Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–6304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.